A phase II multicenter, open-label study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects

Trial Profile

A phase II multicenter, open-label study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 May 2016

At a glance

  • Drugs Sepantronium bromide (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Status changed from recruiting to suspended, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top